Summary

NAT2 rs1801280 and rs1799930 determine your acetylator status — whether you process aromatic amines (from charred meat, tobacco smoke, and certain drugs) quickly or slowly — and slow acetylators need to pay more attention to cooking methods and should mention their status to prescribers of specific medications.

Genotype spectrum

Rapid acetylator

Your phase II acetylation is fast. You clear aromatic amines efficiently.

Intermediate acetylator

Your acetylation capacity is moderate — the most common phenotype. You process most substrates adequately but not as quickly as rapid acetylators.

Slow acetylator

You process aromatic amines slowly — this has both dietary and drug implications. Slow acetylation means heterocyclic amines from charred meat linger longer, and certain drugs accumulate to higher levels at standard doses.

Practical takeaway

For Rapid Acetylators

Cooking awareness:
• You clear aromatic amines efficiently via N-acetylation. But the O-acetylation pathway means rapid acetylation of hydroxylated HCAs can generate DNA-reactive intermediates in the colon.
• Moderate high-temperature meat cooking. Marinades and temperature reduction benefit everyone.
• No specific dietary urgency beyond standard guidelines.

Drug metabolism:
• You may metabolise NAT2-substrate drugs faster than expected. If isoniazid is prescribed, you may need the higher end of dosing.
• Not typically clinically significant unless treatment response is suboptimal.
For Intermediate Acetylators

Balanced approach:
• Standard dietary guidelines with moderate attention to cooking methods.
• Standard drug dosing typically appropriate.
• Mention acetylator status if prescribed isoniazid, hydralazine, or procainamide.
For Slow Acetylators

Cooking method modification — simple, effective:
• Marinate meat before grilling: acid-based marinades (vinegar, citrus, wine) reduce HCA formation by 50-90%. Herb-based marinades (rosemary, thyme, oregano, garlic) provide additional antioxidant HCA reduction.
• Cook at lower temperatures when possible. Braising, baking (under 200°C/400°F), poaching, and steaming produce minimal HCAs compared to grilling, pan-frying, and barbecuing.
• Avoid eating charred/blackened portions of meat. If charring occurs, trim blackened areas.
• Microwave pre-cooking for 2 minutes before grilling reduces HCA formation by 90% (removes some of the HCA precursor creatinine).

Drug awareness — mention to any prescriber:
• Isoniazid (tuberculosis): Slow acetylators have 5x higher drug levels. Higher risk of hepatotoxicity and peripheral neuropathy. Dose adjustment and liver function monitoring needed.
• Hydralazine (blood pressure): Slow acetylators at elevated risk of drug-induced lupus syndrome. Monitor for joint pain, skin rash, fever.
• Procainamide (cardiac arrhythmia): Slow acetylators accumulate active metabolite. Lupus-like syndrome risk.
• Sulfonamide antibiotics: Higher drug levels and increased ADR risk in slow acetylators.
• Caffeine (minor NAT2 substrate): Slow acetylators may experience slightly prolong

Evidence detail

What This Gene Does

NAT2 encodes N-acetyltransferase 2, a phase II detoxification enzyme expressed primarily in the liver and gut epithelium. It catalyses the transfer of an acetyl group from acetyl-CoA to aromatic amine and hydrazine substrates — a conjugation reaction that either activates or deactivates these compounds depending on the specific substrate.

The NAT2 gene is highly polymorphic. Multiple SNPs combine to determine the overall acetylator phenotype: rapid, intermediate, or slow. Two key variants — rs1801280 (T341C, Ile114Thr) and rs1799930 (G590A, Arg197Gln) — are among the most functionally significant. The T allele at rs1801280 and the A allele at rs1799930 each reduce NAT2 enzyme stability and activity. Individuals carrying variant alleles at both positions (or multiple copies of either) are classified as slow acetylators.

Approximately 50-70% of Europeans are slow acetylators — this is not a rare variant but a common polymorphism that was likely neutral or even advantageous in ancestral diets. The clinical relevance emerged with modern exposures: heterocyclic amines from high-temperature meat cooking, aromatic amines from tobacco smoke and industrial chemicals, and drugs that undergo acetylation (isoniazid, hydralazine, sulfonamides, procainamide).

Mechanism

The acetylation reaction:

NAT2 catalyses the transfer of an acetyl group from acetyl-coenzyme A (acetyl-CoA) to the nitrogen atom (N-acetylation) or oxygen atom (O-acetylation) of aromatic amine substrates. The outcome of this reaction — activation or deactivation — depends on the substrate:

N-acetylation (generally deactivating):
Aromatic amines from tobacco smoke, industrial exposure, and heterocyclic amines from cooked meat are N-acetylated by NAT2. N-acetylation typically renders these amines less reactive and more readily excreted. Slow acetylators clear these amines less efficiently, allowing longer exposure of tissues (particularly bladder epithelium) to the parent amine → higher bladder cancer risk in slow acetylators exposed to aromatic amines.

O-acetylation (generally activating):
NAT2 can also O-acetylate N-hydroxylated aromatic amines (already partially activated by phase I CYP1A2). O-acetylation generates acetyloxy esters that spontaneously decompose to highly reactive nitrenium ions — potent DNA-alkylating agents. This is the colon cancer pathway: CYP1A2 hydroxylates heterocyclic amines → NAT2 O-acetylates the hydroxylamine → reactive nitrenium ion → DNA damage in colonic epithelium. In this context, rapid acetylators with high HCA exposure have higher colorectal cancer risk.

The slow acetylator molecular basis:

rs1801280 (T341C, Ile114Thr): The Thr114 substitution destabilises the NAT2 protein through altered intramolecular hydrogen bonding, increasing susceptibility to proteasomal degradation. Less enzyme protein accumulates in hepatocytes.

rs1799930 (G590A, Arg197Gln): The Gln197 substitution reduces catalytic activity directly and also reduces protein stability. This variant is particularly common in European populations.

When both positions carry variant alleles, the combined effect produces the slow acetylator phenotype: both reduced enzyme quantity (faster degradation) and reduced catalytic efficiency of what enzyme remains.

NAT2 Acetylation

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (8)